Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·2 days ago, 03:02 PMREPL+5.12%
Replimune grants CCO Michelle DiNapoli options for 150,000 shares at $15.58, plus 100,000 RSUsPUBT·2 days ago, 03:01 PMREPL+5.12%
Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPLMarket Beat·Aug 18 at 03:40 AMREPL+5.12%
Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings ResultsMarket Beat·Aug 14 at 07:41 PMREPL+5.12%
Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 millionPUBT·Aug 14 at 07:02 AMREPL+5.12%
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate UpdateUnusual Whales·Aug 14 at 07:01 AMREPL+5.12%
Replimune amends filing to correct pre-funded warrant beneficial ownership limitsPUBT·Aug 11 at 05:03 AMREPL+5.12%
18:01 ETREPL INVESTOR ALERT: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuitprnewswire·Aug 10 at 05:02 PMREPL+5.12%
How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For New Melanoma TherapySimplywall·Aug 10 at 02:43 PMREPL+5.12%
Replimune Group Prices Underwritten Offering Of 9.70 Mln Shares At $12.06/Shr; Shares Uprttnews·Aug 10 at 09:09 AMREPL+5.12%
Replimune prices $150M underwritten offering of common stock and pre-funded warrantsTradingView·Aug 10 at 06:53 AMREPL+5.12%
Deadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMorningStar·Aug 7 at 01:48 PMREPL+5.12%
Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling.MSN·Aug 7 at 11:54 AMREPL+5.12%
